TransTissue Technologies

TransTissue Technologies is a German biotechnology company specializing in the development of tissue engineering products for regenerative medicine. Founded in 2001 as a spin-off from the Charité - Universitätsmedizin Berlin, the company focuses on autologous cell therapies for the treatment of cartilage and bone defects. Its core expertise lies in the cultivation of patient-specific cells to create biological implants that promote natural tissue repair. The company was acquired by CO.DON AG, a leader in autologous chondrocyte implantation, and its technologies have been integrated into advanced regenerative treatments for orthopedic applications. Following the acquisition of CO.DON's assets by ReLive Biotechnologies in 2023, TransTissue's scientific legacy continues to support the commercialization of personalized cell therapies across Europe.